This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Vifor Pharma Past Earnings Performance

Past criteria checks 3/6

Key information

16.3%

Earnings growth rate

16.3%

EPS growth rate

Pharmaceuticals Industry Growth	16.3%
Revenue growth rate	7.5%
Return on equity	6.7%
Net Margin	8.1%
Last Earnings Update	31 Dec 2021

Recent past performance updates

Recent updates

I Ran A Stock Scan For Earnings Growth And Vifor Pharma (VTX:VIFN) Passed With Ease

Dec 14

Do Investors Have Good Reason To Be Wary Of Vifor Pharma AG's (VTX:VIFN) 1.6% Dividend Yield?

May 10

Vifor Pharma (VTX:VIFN) Seems To Use Debt Quite Sensibly

Mar 30

Could The Vifor Pharma AG (VTX:VIFN) Ownership Structure Tell Us Something Useful?

Mar 10

How Much Did Vifor Pharma's(VTX:VIFN) Shareholders Earn From Share Price Movements Over The Last Year?

Feb 19

Key Things To Consider Before Buying Vifor Pharma AG (VTX:VIFN) For Its Dividend

Jan 15

Vifor Pharma AG's (VTX:VIFN) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Dec 24

Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?

Dec 01

Getting In Cheap On Vifor Pharma AG (VTX:VIFN) Might Be Difficult

Jul 17

Revenue & Expenses Breakdown
Beta

How Vifor Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SWX:VIFN Revenue, expenses and earnings (CHF Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 21	1,812	147	544	225
30 Jun 21	1,753	213	542	155
31 Mar 21	1,757	176	551	175
31 Dec 20	1,762	139	560	194
30 Jun 20	1,709	93	553	249
31 Mar 20	1,732	101	563	231
31 Dec 19	1,754	108	573	212
30 Sep 19	1,845	129	588	226
30 Jun 19	1,784	100	576	224
31 Mar 19	1,711	126	571	215
31 Dec 18	1,639	152	567	206
30 Sep 18	1,571	157	571	199
30 Jun 18	1,504	162	576	191
31 Mar 18	1,441	98	561	188
31 Dec 17	1,378	34	546	185
30 Sep 17	1,345	26	544	173
30 Jun 17	1,312	18	543	162
31 Mar 17	1,283	82	503	142
31 Dec 16	1,254	147	464	122
30 Sep 16	1,944	218	525	84
30 Jun 16	2,635	290	587	46
31 Mar 16	3,265	295	654	23
31 Dec 15	3,896	301	722	0

Quality Earnings: VIFN has high quality earnings.

Growing Profit Margin: VIFN's current net profit margins (8.1%) are higher than last year (7.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VIFN's earnings have grown by 16.3% per year over the past 5 years.

Accelerating Growth: VIFN's earnings growth over the past year (5.7%) is below its 5-year average (16.3% per year).

Earnings vs Industry: VIFN earnings growth over the past year (5.7%) underperformed the Pharmaceuticals industry 18.2%.

Return on Equity

High ROE: VIFN's Return on Equity (6.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Vifor Pharma Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

Recent updates

Cancellation of Remaining Publicly Held Registered Shares of Vifor Pharma

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

High number of new directors

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Price target increased to CHF144

Investor sentiment improved over the past week

Vifor Pharma and CSL Confirm Merger Talks

I Ran A Stock Scan For Earnings Growth And Vifor Pharma (VTX:VIFN) Passed With Ease

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Vifor Says Regularly in Talks with Other Market Participants After Reports

Investor sentiment improved over the past week

Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Here's Why We Think Vifor Pharma (VTX:VIFN) Is Well Worth Watching

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Chief Executive Officer Stefan Schulze has left the company

Is Vifor Pharma (VTX:VIFN) A Risky Investment?

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Independent Director has left the company

Independent Director has left the company

Do Investors Have Good Reason To Be Wary Of Vifor Pharma AG's (VTX:VIFN) 1.6% Dividend Yield?

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Upcoming dividend of CHF2.00 per share

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Vifor Pharma (VTX:VIFN) Seems To Use Debt Quite Sensibly

Could The Vifor Pharma AG (VTX:VIFN) Ownership Structure Tell Us Something Useful?

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Earnings beat expectations, revenue disappoints

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

New 90-day low: CHF114

How Much Did Vifor Pharma's(VTX:VIFN) Shareholders Earn From Share Price Movements Over The Last Year?

New 90-day low: CHF117

Vifor Pharma Announces Board Changes

Key Things To Consider Before Buying Vifor Pharma AG (VTX:VIFN) For Its Dividend

New 90-day high: CHF136

Vifor Pharma AG's (VTX:VIFN) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?

Analysts update estimates

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Market bids up stock over the past week

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Analysts update estimates

New 90-day low: CHF120

New 90-day low: CHF122

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

New 90-day low - CHF124

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

First half earnings released

New 90-day low - CHF134

Getting In Cheap On Vifor Pharma AG (VTX:VIFN) Might Be Difficult

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta